21Shares XRP ETF said its sponsor, 21Shares US, notified CF Benchmarks on June 30, 2026 that it will terminate the pricing benchmark licensing agreement effective August 31, 2026. The agreement licenses the CME CF XRP–Dollar Reference Rate (New York Variant) used to value the Trust’s shares and calculate NAV. The termination is pursuant to the agreement’s terms and follows the Sponsor’s plan to transition to a new benchmark provider, expected to be FTSE. No fees or penalties were disclosed.
Agreement details:
- Agreement terminated: Pricing benchmark licensing agreement for CME CF XRP–Dollar Reference Rate (NY Variant)
- Counterparty: CF Benchmarks
- Original agreement date: N/A
- Termination date: Aug 31 2026
- Termination type: Early
- Exit fees / payments: None
- Reason: Transition to a new benchmark provider (FTSE)
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.